2,4,6-Tricyano-heptan | 17199-93-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2,4,6-Tricyano-heptan
• 英文别名: Heptane-2,4,6-tricarbonitrile；1-methylhexane-1,3,5-tricarbonitrile
• CAS: 17199-93-8
• 化学式: C₁₀H₁₃N₃
• 分子量: 175.233
• InChiKey: ZVRBCRRMIOLSAZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  71.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,4,6-Tricyano-heptan 在 水 、 氧化亚氮 作用下， 以 1,4-二氧六环 、 丙酮 为溶剂， 反应 72.0h， 生成 sodium 2,4,6-tricyanoheptane-2,4-bisdiazeniumdiolate
  参考文献：
  名称：

  一氧化氮释放织物和其他丙烯腈基二氮烯二醇盐

  摘要：

  将二氮烯二醇 [−N(O)NO−] 官能团连接到聚合物上在药理学上越来越受到关注，因为它们能够在暴露于水环境时自发产生高达 2 摩尔当量的生物活性一氧化氮 (NO)，但又限制了对物理上接近的部位的生理影响。通过 NO 与处理含有 1,3-二氰基的丙烯腈基聚合物时产生的脒的烯二胺互变异构体反应形成的碳键二氮烯二醇化聚合物被证明是持久的 NO 释放材料，可在室温下储存数月. 已经制备了释放 NO 的聚丙烯腈 (PAN) 粉末和织物衍生物，并且在 37 °C 下暴露于 pH 7.4 磷酸盐缓冲液时，可释放 NO 超过 80 天。PAN/NO 粉末已被证明可抑制受损大鼠颈动脉中新生内膜增生的形成。也已从聚（苯乙烯-共-丙烯腈）制备释放 NO (> 7 d) 的二氮烯二醇酯。

  DOI：

  10.1021/ja0686864
• 作为产物：
  描述：

  4-carboxy-2,4,6-tricyanoheptane 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以73%的产率得到2,4,6-Tricyano-heptan
  参考文献：
  名称：

  一氧化氮释放织物和其他丙烯腈基二氮烯二醇盐

  摘要：

  将二氮烯二醇 [−N(O)NO−] 官能团连接到聚合物上在药理学上越来越受到关注，因为它们能够在暴露于水环境时自发产生高达 2 摩尔当量的生物活性一氧化氮 (NO)，但又限制了对物理上接近的部位的生理影响。通过 NO 与处理含有 1,3-二氰基的丙烯腈基聚合物时产生的脒的烯二胺互变异构体反应形成的碳键二氮烯二醇化聚合物被证明是持久的 NO 释放材料，可在室温下储存数月. 已经制备了释放 NO 的聚丙烯腈 (PAN) 粉末和织物衍生物，并且在 37 °C 下暴露于 pH 7.4 磷酸盐缓冲液时，可释放 NO 超过 80 天。PAN/NO 粉末已被证明可抑制受损大鼠颈动脉中新生内膜增生的形成。也已从聚（苯乙烯-共-丙烯腈）制备释放 NO (> 7 d) 的二氮烯二醇酯。

  DOI：

  10.1021/ja0686864

文献信息

• Janout, Vaclav; Cefelin, Pavel, Collection of Czechoslovak Chemical Communications, 1980, vol. 45, # 7, p. 1928 - 1936
  作者：Janout, Vaclav、Cefelin, Pavel

  DOI：——

  日期：——
• NITRIC OXIDE-RELEASING DIAZENIUMDIOLATED ACRYLONITRILE-BASED POLYMERS, AND COMPOSITIONS, MEDICAL DEVICES, AND USES THEREOF
  申请人：Government of the United States of America, Represented by the Secretary, Department of Health and Human Services

  公开号：EP1794195B1

  公开（公告）日：2014-12-17
• Use of core/shell particles
  申请人：Winkler Holger

  公开号：US20070160521A1

  公开（公告）日：2007-07-12

  The invention relates to the use of core/shell particles, the core of which essentially comprises a degradable polymer with an essentially mono-disperse size distribution and the shell of which forms a matrix, which can be pyrolysed to give a carbon matrix, for the production of shaped bodies with regularly-arranged cavities and the corresponding shaped bodies.
• Nitric Oxide-Releasing Diazeniumdiolated Acrylonitrile-Based Polymers, and Compositions, Medical Devices, and Uses Thereof
  申请人：Hrabie A. Joseph

  公开号：US20070292471A1

  公开（公告）日：2007-12-20

  The invention described herein provides for novel nitric oxide-releasing polymers that comprise at least two adjacent units derived from acrylonitrile monomer units and containing at least one carbon-bound diazeniumdiolate. The diazeniumdiolated acrylonitrile-derived polymers can be used in medical devices therapeutically. Accordingly, the invention also provides a method of treating a biological disorder and a method of promoting angiogenesis that includes administering a medical device comprising a nitric oxide-releasing polymer comprising at least two adjacent units of acrylonitrile before exposure to nitric oxide and at least one nitric oxide releasing N 2 O 2 — group, wherein the N 2 O 2 — group is attached directly to the polyacrylonitrile backbone, to a specific location on or within the mammal in an amount effective to treat the biological disorder or promote angiogenesis.
• NITRIC OXIDE-RELEASING DIAZENIUMDIOLATED COMPOUNDS
  申请人：Hrabie Joseph A.

  公开号：US20110282060A1

  公开（公告）日：2011-11-17

  The invention described herein provides for novel nitric oxide-releasing polymers that comprise at least two adjacent units derived from acrylonitrile monomer units and containing at least one carbon-bound diazeniumdiolate. The diazeniumdiolated acrylonitrile-derived polymers can be used in medical devices therapeutically. Accordingly, the invention also provides a method of treating a biological disorder and a method of promoting angiogenesis that includes administering a medical device comprising a nitric oxide-releasing polymer comprising at least two adjacent units of acrylonitrile before exposure to nitric oxide and at least one nitric oxide releasing N 2 O 2 − group, wherein the N 2 O 2 − group is attached directly to the polyacrylonitrile backbone, to a specific location on or within the mammal in an amount effective to treat the biological disorder or promote angiogenesis.